包装 | 价格(元) |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
分子式 | C19H18N6O2 | ||||||||||||||||||||||||
分子量 | 362.39 | ||||||||||||||||||||||||
储存条件 | 4°C, away from moisture | ||||||||||||||||||||||||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. | ||||||||||||||||||||||||
Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request | ||||||||||||||||||||||||
产品描述 | IC50: 6 nM (FLT3), 140 nM (CLK1), 220 nM (RPS6KA), 520 nM (VEGFR2), and 120 nM (FGFR2)[1] AKN-028 acetate, a noveltyrosine kinase (TK)inhibitor, is a potent, orally activeFMS-like receptor tyrosine kinase 3 (FLT3)inhibitor with anIC50value of 6 nM. AKN-028 acetate inhibits FLT3 autophosphorylation. AKN-028 acetate induces dose-dependent cytotoxic response (meanIC50=1 μM). AKN-028 acetate inducesapoptosisby activation of caspase 3. AKN-028 acetate can be used in research of acute myeloid leukemia (AML)[1]. AKN-028 (0.1 nM-100 μM; 15 h; mouse embryonal fibroblasts and human acute megakaryoblastic leukemia M07 cells) acetate inhibits FLT3 and KIT autophosphorylation in a dose-dependent manner[1]. Cell Cytotoxicity Assay[1]
Western Blot Analysis[1]
AKN-028 (15 mg/kg; i.h.; twice daily, for 6 days; male C57 black mice with MV4-11 xenografts) acetate inhibits growth of primary AML and MV4-11 cells in mice[1].
|